Response to Ritlecitinib Treatment Based on Salt Improvement Scores in Patients With Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
Studysummary This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of ritlecitinib in patients aged ≥12 years with alopecia areata (AA) and ≥50% scalp hair loss. Patients received varying doses of ritlecitinib or placebo for 24 weeks, with the placebo group switching to ritlecitinib thereafter. By Week 24, a higher proportion of patients treated with ritlecitinib achieved significant improvements in SALT scores compared to placebo, with 29-43% achieving SALT50, 13-31% achieving SALT75, 9-19% achieving SALT90, and 2-7% achieving SALT100. These improvements continued through Week 48, with 43-55% achieving SALT50, 30-46% achieving SALT75, 21-30% achieving SALT90, and 7-14% achieving SALT100. The study concluded that ritlecitinib treatment leads to significant scalp hair regrowth, with higher doses yielding better results.
